Results from the Phase III HAVEN 1 study published in the New England Journal of Medicine and a positive reception of data presented at the International Society on Thrombosis and Haemostasis (ISTH) Congress in Berlin bode well for approval of Roche'semicizumab in hemophilia.
Emicizumab (ACE910) is a bispecific monoclonal antibody that binds to both Factor IXa and X. The drug is being positioned...






